Mitofusion-2-mediated alleviation of insulin resistance in rats through reduction in lipid intermediate accumulation in skeletal muscle
© Zhang et al.; licensee BioMed Central Ltd. 2013
Received: 13 March 2013
Accepted: 25 June 2013
Published: 1 July 2013
Increased lipid accumulation and mitochondrial dysfunction within skeletal muscle have been shown to be strongly associated with insulin resistance. However, the role of mitofusion-2 (MFN2), a key factor in mitochondrial function and energy metabolism, in skeletal muscle lipid intermediate accumulation remains to be elucidated.
A high-fat diet resulted in insulin resistance as well as accumulation of cytosolic lipid intermediates and down-regulation of MFN2 and CPT1 in skeletal muscle in rats, while MFN2 overexpression improved insulin sensitivity and reduced lipid intermediates in muscle, possibly by upregulation of CPT1 expression.
MFN2 overexpression can rescue insulin resistance, possibly by upregulating CPT1 expression leading to reduction in the accumulation of lipid intermediates in skeletal muscle. These observations contribute to the investigations of new diabetes therapies.
Type 2 diabetes is characterized by insulin resistance (which affects skeletal muscle, liver and other insulin-sensitive tissues) and by defective insulin secretion . Increased adiposity and lipid accumulation within the skeletal muscle and mitochondrial dysfunction have been shown to be strongly associated with insulin resistance . Important studies have appeared in recent years to reinforce the view that it is active lipid intermediates such as long-chain fatty acid CoAs (LCCoAs), diacylglycerols (DAG) and ceramides (CEA) that result in lipid-induced muscle insulin resistance [3, 4].
Skeletal muscle is quantitatively the major contributor to whole body insulin-mediated glucose disposal. Fat accumulation in muscle negatively impacts insulin-mediated glucose uptake. The hypothesis that insulin resistance is related to lipid accumulation in muscle dates back to studies reported 15–20 years ago showing that triglycerides accumulate in muscle in rats fed a high-fat diet, which is coincident with insulin resistance. Since then the relevance of muscle lipid accumulation to insulin resistance in humans has been demonstrated, and basic studies have indicated plausible mechanisms whereby lipid accumulation could generate insulin resistance .
There may be multiple metabolic causes for increased cytosolic lipid accumulation in muscle in insulin-resistant states. Theoretically, a decrease in fatty acid β-oxidation can lead to lipid accumulation. The acceleration of fatty acid β-oxidation may lessen the potential for insulin resistance [6, 7].
CPT1 is the rate-limiting enzyme that controls the transfer of cytosolic LCCoAs into mitochondria for oxidation. Slight increases in CPT1 expression in muscle can direct lipids away from storage and into oxidation, at least in rodents, indicating the importance of this regulatory step in opposing cytosolic lipid accumulation . Mitochondrial dysfunction has been reported in skeletal muscle in type 2 diabetic patients [9–11]. There is evidence that insulin-resistant obese individuals with type 2 diabetes have approximately 30% fewer mitochondria in their skeletal muscle than age-matched healthy controls . It is likely that decreased mitochondrial mass is a defect in type 2 diabetes.
Mitofusin-2 (MFN2) protein is a dynamin-related protein with GTPase activity anchored in the external mitochondrial membrane . MFN2 is abundantly expressed in skeletal muscle [14–16] and its activity is crucial in the maintenance of mitochondrial tubules in cultured muscle cells . Overexpression of MFN2 in HeLa cells causes perinuclear aggregation of mitochondria, a marked enhancement of mitochondrial membrane potential and increased glucose oxidation . Detection of mitochondrial function includes measures of fatty acid oxidation and oxidative phosphorylation. Indicators of fatty acid oxidation potential include measurements of enzymes associated with fatty acid transport protein into the cell (fatty acid transport protein (CD36) , fatty acid transport into the mitochondria (carnitine palmitoyltransferase I [CPT1] , and fatty acid β-oxidation (β-hydroxyacyl-CoA dehydrogenase [HADH] .
Previous studies confirmed that high-fat diets induced insulin resistance and MFN2 down-regulation in rat muscle  (David Sebastián, et al. 2012). However, the roles of MFN2, a key factor for mitochondria function and energy metabolism, in skeletal muscle lipid intermediate accumulation remain to be elucidated.
In this study, we established a model of insulin resistance in rats by provision of a high-fat diet. Furthermore, an MFN2-expressing adenovirus was used to investigate the mechanism by which MFN2 relieves skeletal muscle lipid intermediate accumulation and ameliorates insulin resistance.
The animal experiments were conducted according to protocols reviewed and approved by the Animal Experimental Ethics Committee of Hebei General Hospital, Shijiazhuang, China (approval ID: HBGH-2010027). Four-week-old male Sprague Dawley (SD) rats (70 ± 10 g) were housed individually at 22°C, in 12 h/12 h light/dark conditions and 50% relative humidity. SD rats were divided randomly into two groups of 36: normal diet (8 N) group (n = 12), high-fat diet (8 F) group (n = 24). The 8 N group was fed with a standard carbohydrate diet (10.3% fat, 24.2% protein, and 65.5% carbohydrate), while the 8 F group was fed with a high-fat diet (59.8% fat, 20.1% protein, and 20.1% carbohydrate). After 8 weeks of feeding, insulin resistance in each group was evaluated by glucose infusion rate (GIR) using the hyperinsulinemic euglycemic clamp technique in the conscious state. Six randomly selected rats in each group were then sacrificed by exsanguination. Fasting blood glucose (BG) levels were measured using an Accu-chek Active Meter (ACCU-CHEK® Active; Roche,Basel,Switzerland), Fasting serum insulin levels were determined with a rat insulin ELISA kit (Crystal Chem. Inc.). Skeletal muscle tissue was rapidly removed, freeze-clamped in liquid nitrogen and stored at -80°C. The high-fat diet (8 F) group was divided randomly into three groups: high-fat diet control (control) group, empty adenovirus (Ad) group, and MFN2 overexpression (Ad-MFN2) group. All rats were then infected with PBS as a control, empty adenovirus or the MFN2 overexpressing adenovirus (109 v.p./kg body weight) once a week for 3 weeks. The MFN2 overexpressing adenovirus (Ad-MFN2) and the empty control adenovirus (Ad) were obtained from Dr Rui Zhang, Hebei Medical University . Except for the periods of pretest overnight fasting and the immediate postoperative period, animals had free access to water and chow. Hyperinsulinemic clamp studies were repeated to confirm the amelioration of insulin resistance. Overnight-fasted rats were anesthetized with sodium pentobarbital (3% Pelltobarbitalum Natricum, 60 mg/kg, intraperitoneally) and blood samples were obtained from the abdominal aorta. Skeletal muscle tissue was immediately removed, freeze-clamped in liquid nitrogen and stored at -80°C.
Hyperinsulinemic euglycemic clamp
Insulin sensitivity can be measured using a variety of techniques that are commonly employed in diabetes research and care. Of these, the hyperinsulinemic euglycemic clamp is the gold-standard method. Hyperinsulinemic clamp studies were performed as previously described . Rats were placed under general anesthesia (3% Pelltobarbitalum Natricum, 60 mg/kg, intraperitoneally) and catheters were inserted into the right jugular vein and the carotid arteries of rats and exteriorized from the back of the neck subcutaneously. At the end, the catheters were flushed with isotonic saline containing heparin (50 units/ml). Rats were allowed a minimum of 3 days for full recovery and only those that had lost less than 5% of their preoperative weights were used in experiments. Euglycemic-hyperinsulinemic clamps were performed on fasted, awake, and unrestrained animals. Insulin (4 mU/kg/min) was infused through the jugular vein catheter from 0 to 90 min. Glucose concentrations were clamped at euglycemic levels by a variable rate infusion of 30% glucose. BG levels were monitored with a glucometer (ACCU-CHEK® Active; Roche), and GIR were adjusted every 5–10 min as required. A stable GIR was obtained within approximately 60 minutes of the insulin infusion and maintained thereafter. At steady state, mean GIR was normalized to body weight.
Skeletal muscle samples to be used for electron microscopy were cut into small pieces (1 × 1 × 2 mm) and fixed in 2.5% glutaraldehyde, post-fixed in 1% osmium tetroxide, dehydrated, and embedded in Epon in the longitudinal orientation. After an initial low-power screening of semithin (300 nm) sections stained with toluidine blue to optimize the plane of sectioning, ultrathin (60 nm) longitudinal sections were cut for each sample. The sections were mounted on copper grids and stained with lead citrate and uranyl acetate. For each biopsy, at least 10 longitudinal sections were examined by transmission electron microscopy (TEM) (H-7500, Japanese Hitachi Ltd) at an accelerating voltage of 80 kV. A minimum of 10 micrographs were taken at 15,000 × magnification.
Determination of skeletal muscle triglycerides, long-chain fatty acid CoAs, diacylglycerol and ceramides
Triacylglycerols were extracted with a 2:1 chloroform-methanol solution and quantified with an enzymatic assay kit (Wako Pure Chemical Industries) as previously described . Extraction of long-chain fatty acid CoAs, diacylglycerol and ceramides via HPLC was performed as previously described [24, 25].
Primer sequences for quantitative PCR
Forward primer (5'-3')
Reverse primer (5'-3')
Western blot analysis
Frozen skeletal muscle was prepared with lysis buffer (1% Triton X-100, 150 mM NaCl, 10 mM Tris–HCl (pH 7.4); 1 mM EDTA, 1 mM EGTA (pH 8.0); 0.2 mM Na3VO4, 0.2 mM phenylmethylsulfonyl fluoride, and 0.5% NP-40). Equal amounts of proteins were separated by 10% SDS-PAGE, and electrotransferred to PVDF membranes (Millipore, USA), and then were blocked with 5% BSA for 2 h at room temperature. Membranes were incubated with appropriately diluted rabbit anti-rat primary antibodies for detection of MFN2 (Bioworld Technology, Inc.), CPT1 (Santa Cruz), CD36 (Santa Cruz) or mouse anti-rat β-actin (Cell Signaling Technology) overnight at 4°C. Membranes were then incubated with the relevant secondary antibodies (MFN2, CD36, CPT1: anti-rabbit IgG; β-actin: anti-mouse IgG; all from Santa Cruz) for 2 h at 20°C. Proteins were detected with the enhanced chemiluminescence (ECL) detection system. β-actin was served as an internal control protein.
All experiments were repeated at least three times. Values are represented as means ± SD. All statistical analyses were performed with the SPSS statistical package (SPSS 16.0 software). Statistical significance was assessed by ANOVA (post-hoc used Student-Newman-Keuls test) and unpaired Student’s t-tests (P-values < 0.05 were considered significant).
Evaluation of insulin sensitivity in high-fat diet treated rats
High-fat diet increased the accumulation of lipid intermediates in skeletal muscle, and downregulated the expression of MFN2 and CPT1
Changes in mitochondrial morphology following MFN2 overexpression
Overexpression of MFN2 ameliorated insulin resistance induced by a high-fat diet in rats
Overexpression of MFN2 improved accumulation of muscle lipid intermediates in high-fat diet rats
Overexpression of MFN2 increased CPT1 expression
Our study suggested that MFN2 expression and insulin sensitivity were inhibited by a high-fat diet, with concomitant accumulation of lipid intermediates in the muscle. This is in agreement with previously reported findings . Furthermore, we demonstrated that overexpression of MFN2 recovered insulin sensitivity and reduced lipid accumulation, which may be associated with CPT1 upregulation in skeletal muscle.
Over-consumption of fat is a significant contributor to the development of obesity and insulin resistance. High-fat-diets enriched with lard were widely used to induce an obese animal model of insulin resistance . In this study, lipid accumulation in skeletal muscle was observed in rats fed a high-fat diet, while MFN2 and CPT1 expression was downregulated dramatically and CD36 expression was increased. This may suggest that the lower expression of MFN2 and CPT1 is a consequence of mitochondrial dysfunction, while the higher expression of CD36 is compensational for increased blood plasma free fatty acid levels induced by a high-fat diet. When the levels of fatty acids transported into the cytosol exceed the capacity for mitochondrial oxidation, lipid or lipid intermediates are deposited in skeletal muscle.
Normally, the binding of insulin to insulin receptors stimulates autophosphorylation of tyrosine residues and subsequent activation of a receptor tyrosine kinase. This tyrosine kinase phosphorylates multiple intracellular substrates, including insulin receptor substrate (IRS) 1 and 2, which play significant roles in the insulin response. This is mediated by IRS activation of phosphatidylinositol 3-kinase (PI 3-kinase), a critical player in insulin signaling particularly with regard to glucose homeostasis. Phosphatidylinositol 3-kinase facilitates the translocation of the insulin-responsive glucose transporter (GLUT4) to the plasma membrane through a mechanism that is thought to be mediated by phosphorylation . Recent studies confirm that lipid intermediates such as long-chain fatty acid CoA species (LCCoAs), diacylglycerol (DAG), and ceramides (CEA) disrupt one or more of the early steps in insulin signal transduction. These compounds have been implicated in the activation of isoforms of PKC, leading to impairment of phosphatidylinositol 3-kinase (PI3K) activity and inhibition of the activation of PKB (Akt/PKB) as well as decreased insulin-induced glucose transportation and glycogen synthesis .
Mitochondria are the primary cellular sites for fatty acid oxidation and utilization. Mitochondrial dysfunction plays an important role in the development of insulin resistance in skeletal muscle . MFN2 is a proliferation-inhibiting gene encoding a mitochondrial fusion protein that participates in the maintenance of mitochondrial morphology and regulates mitochondrial metabolism and intracellular signaling [16, 30]. Although the central role of MFN2 in mitochondrial metabolism is well-established , its roles in insulin resistance in skeletal muscle and muscle lipid intermediate accumulation remain uncertain.
Mitochondrial β-oxidation represents a crucial process in energy metabolism and is tightly regulated by interactions between the key enzymes carnitine palmitoyltransferase 1 (CPT1) and acetyl-CoA carboxylase (ACC) via the intermediate malonyl-CoA. CPT1 is an integral membrane protein that associates with the mitochondrial outer membrane through transmembrane regions in the peptide chain. Both MFN2 and CPT1 are regulated by peroxisome proliferators-activated receptor coactivator-1 (PGC1). CD36 is a multifunctional membrane-associated glycoprotein with a molecular weight of 88 kDa. It plays an important role in the uptake of long-chain fatty acids (LCFAs) in skeletal muscle . Superficially, there are no direct association between CPT1 and CD36; however, more recent information suggests that CPT1 may not act alone in the regulation of fatty acyl-CoA entry into the mitochondria. Recent studies have demonstrated that the fatty acid translocase FAT/CD36 is present on the mitochondrial membrane of both rodent and human skeletal muscle, where it plays an important role in regulating fatty acid oxidation . Above all, the elucidation of the highly complex relationships among MFN2, CPT1 and CD36 are of critical significance.
In the current study, our data demonstrate that overexpression of MFN2 significantly restored insulin sensitivity and reduced the levels of BG and plasma insulin in rats, suggesting MFN2 as a potential therapeutic target in insulin resistance. It can be speculated that the mechanism underlying the improvement in insulin resistance associated with MFN2 overexpression is mediated by improved mitochondrial function. Consequently, with the upregulation of CPT1, the redundant lipid intermediates in the cytosolic were transported into the mitochondria for β-oxidation, thus relieving the damage to insulin signaling resulting from the accumulated lipid intermediates.
In conclusion, our data suggest that MFN2 ameliorates insulin resistance induced by a high-fat diet through upregulation of CPT1, which relieves lipid intermediates accumulation in skeletal muscle. Therefore MFN2 is implicated as a potential target for the treatment of insulin resistance and metabolic syndromes.
This work was supported by grants from the National Natural Science Foundations of China (30971391, 81170742) and Hebei Natural Science Foundation of China (C2010001638, C2011307008).
- DeFronzo RA: Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988, 37: 667-687.View ArticlePubMedGoogle Scholar
- Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest. 2000, 106: 171-176. 10.1172/JCI10583.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu L, Zhang Y, Chen N, Shi X, Tsang B, Yu YH: Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance. J Clin Invest. 2007, 117: 1679-1689. 10.1172/JCI30565.PubMed CentralView ArticlePubMedGoogle Scholar
- Schenk S, Horowitz JF: Acute exercise increases triglyceride synthesis in skeletal muscle and prevents fatty acid-induced insulin resistance. J Clin Invest. 2007, 117: 1690-1698. 10.1172/JCI30566.PubMed CentralView ArticlePubMedGoogle Scholar
- Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm DJ, Storlien LH: Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes. 1991, 40: 1397-1403. 10.2337/diabetes.40.11.1397.View ArticlePubMedGoogle Scholar
- Atkinson LL, Kozak R, Kelly SE, Onay Besikci A, Russell JC, Lopaschuk GD: Potential mechanisms and consequences of cardiac triacylglycerol accumulation in insulin-resistant rats. Am J Physiol Endocrinol Metab. 2003, 284: E923-E930.View ArticlePubMedGoogle Scholar
- Young ME, Guthrie PH, Razeghi P, Leighton B, Abbasi S, Patil S, Youker KA, Taegtmeyer H: Impaired long-chain fatty acid oxidation and contractile dysfunction in the obese Zucker rat heart. Diabetes. 2002, 51: 2587-2595. 10.2337/diabetes.51.8.2587.View ArticlePubMedGoogle Scholar
- Bruce CR, Brolin C, Turner N, Cleasby ME, van der Leij FR, Cooney GJ, Kraegen EW: Overexpression of carnitine palmitoyltransferase I in skeletal muscle in vivo increases fatty acid oxidation and reduces triacylglycerol esterification. Am J Physiol Endocrinol Metab. 2007, 292: E1231-E1237.View ArticlePubMedGoogle Scholar
- Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI: Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004, 350: 664-671. 10.1056/NEJMoa031314.PubMed CentralView ArticlePubMedGoogle Scholar
- Asmann YW, Stump CS, Short KR, Coenen-Schimke JM, Guo Z, Bigelow ML, Nair KS: Skeletal muscle mitochondrial functions, mitochondrial DNA copy numbers, and gene transcript profiles in type 2 diabetic and nondiabetic subjects at equal levels of low or high insulin and euglycemia. Diabetes. 2006, 55: 3309-3319. 10.2337/db05-1230.View ArticlePubMedGoogle Scholar
- Stump CS, Short KR, Bigelow ML, Schimke JM, Nair KS: Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts. Proc Natl Acad Sci USA. 2003, 100: 7996-8001. 10.1073/pnas.1332551100.PubMed CentralView ArticlePubMedGoogle Scholar
- Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, Kelley DE: Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes. 2005, 54: 8-14. 10.2337/diabetes.54.1.8.View ArticlePubMedGoogle Scholar
- Liesa M, Palacin M, Zorzano A: Mitochondrial dynamics in mammalian health and disease. Physiol Rev. 2009, 89: 799-845. 10.1152/physrev.00030.2008.View ArticlePubMedGoogle Scholar
- Bach D, Pich S, Soriano FX, Vega N, Baumgartner B, Oriola J, Daugaard JR, Lloberas J, Camps M, Zierath JR, Rabasa-Lhoret R, Wallberg-Henriksson H, Laville M, Palacin M, Vidal H, Rivera F, Brand M, Zorzano A: Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem. 2003, 278: 17190-17197. 10.1074/jbc.M212754200.View ArticlePubMedGoogle Scholar
- Santel A, Fuller MT: Control of mitochondrial morphology by a human mitofusin. J Cell Sci. 2001, 114: 867-874.PubMedGoogle Scholar
- Santel A, Frank S, Gaume B, Herrler M, Youle RJ, Fuller MT: Mitofusin-1 protein is a generally expressed mediator of mitochondrial fusion in mammalian cells. J Cell Sci. 2003, 116: 2763-2774. 10.1242/jcs.00479.View ArticlePubMedGoogle Scholar
- Pich S, Bach D, Briones P, Liesa M, Camps M, Testar X, Palacin M, Zorzano A: The Charcot-Marie-Tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through expression of OXPHOS system. Hum Mol Genet. 2005, 14: 1405-1415. 10.1093/hmg/ddi149.View ArticlePubMedGoogle Scholar
- Schaffer JE, Lodish HF: Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein. Cell. 1994, 79: 427-436. 10.1016/0092-8674(94)90252-6.View ArticlePubMedGoogle Scholar
- McGarry JD, Brown NF: The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem. 1997, 244: 1-14. 10.1111/j.1432-1033.1997.00001.x.View ArticlePubMedGoogle Scholar
- Helge JW, Kiens B: Muscle enzyme activity in humans: role of substrate availability and training. Am J Physiol. 1997, 272: R1620-R1624.PubMedGoogle Scholar
- Sebastian D, Hernandez-Alvarez MI, Segales J, Sorianello E, Munoz JP, Sala D, Waget A, Liesa M, Paz JC, Gopalacharyulu P, Oresic M, Pich S, Burcelin R, Palacin M, Zorzano A: Mitofusin 2 (Mfn2) links mitochondrial and endoplasmic reticulum function with insulin signaling and is essential for normal glucose homeostasis. Proc Natl Acad Sci USA. 2012, 109: 5523-5528. 10.1073/pnas.1108220109.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang R, Han M, Zheng B, Li YJ, Shu YN, Wen JK: Kruppel-like factor 4 interacts with p300 to activate mitofusin 2 gene expression induced by all-trans retinoic acid in VSMCs. Acta Pharmacol Sin. 2010, 31: 1293-1302. 10.1038/aps.2010.96.PubMed CentralView ArticlePubMedGoogle Scholar
- Meirelles K, Ahmed T, Culnan DM, Lynch CJ, Lang CH, Cooney RN: Mechanisms of glucose homeostasis after Roux-en-Y gastric bypass surgery in the obese, insulin-resistant Zucker rat. Ann Surg. 2009, 249: 277-285. 10.1097/SLA.0b013e3181904af0.PubMed CentralView ArticlePubMedGoogle Scholar
- Gao S, Kinzig KP, Aja S, Scott KA, Keung W, Kelly S, Strynadka K, Chohnan S, Smith WW, Tamashiro KL, Ladenheim EE, Ronnett GV, Tu Y, Birnbaum MJ, Lopaschuk GD, Moran TH: Leptin activates hypothalamic acetyl-CoA carboxylase to inhibit food intake. Proc Natl Acad Sci USA. 2007, 104: 17358-17363. 10.1073/pnas.0708385104.PubMed CentralView ArticlePubMedGoogle Scholar
- Bose R, Kolesnick R: Measurement of ceramide levels by the diacylglycerol kinase reaction and by high-performance liquid chromatography-fluorescence spectrometry. Methods Enzymol. 2000, 322: 373-378.View ArticlePubMedGoogle Scholar
- Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA, Scholmerich J, Bollheimer LC: Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J Mol Endocrinol. 2006, 36: 485-501. 10.1677/jme.1.01909.View ArticlePubMedGoogle Scholar
- Chow L, From A, Seaquist E: Skeletal muscle insulin resistance: the interplay of local lipid excess and mitochondrial dysfunction. Metabolism. 2010, 59: 70-85. 10.1016/j.metabol.2009.07.009.PubMed CentralView ArticlePubMedGoogle Scholar
- Sebastian D, Herrero L, Serra D, Asins G, Hegardt FG: CPT I overexpression protects L6E9 muscle cells from fatty acid-induced insulin resistance. Am J Physiol Endocrinol Metab. 2007, 292: E677-E686.View ArticlePubMedGoogle Scholar
- Honda S, Aihara T, Hontani M, Okubo K, Hirose S: Mutational analysis of action of mitochondrial fusion factor mitofusin-2. J Cell Sci. 2005, 118: 3153-3161. 10.1242/jcs.02449.View ArticlePubMedGoogle Scholar
- Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC: Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol. 2003, 160: 189-200. 10.1083/jcb.200211046.PubMed CentralView ArticlePubMedGoogle Scholar
- Yoshizumi T, Nozaki S, Fukuchi K, Yamasaki K, Fukuchi T, Maruyama T, Tomiyama Y, Yamashita S, Nishimura T, Matsuzawa Y: Pharmacokinetics and metabolism of 123I-BMIPP fatty acid analog in healthy and CD36-deficient subjects. J Nucl Med. 2000, 41: 1134-1138.PubMedGoogle Scholar
- Campbell SE, Tandon NN, Woldegiorgis G, Luiken JJ, Glatz JF, Bonen A: A novel function for fatty acid translocase (FAT)/CD36: involvement in long chain fatty acid transfer into the mitochondria. J Biol Chem. 2004, 279: 36235-36241. 10.1074/jbc.M400566200.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.